Rockefeller Capital Management L.P. Has $4.56 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)

Rockefeller Capital Management L.P. reduced its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 61.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 68,205 shares of the company's stock after selling 108,516 shares during the period. Rockefeller Capital Management L.P.'s holdings in Moderna were worth $4,563,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in MRNA. Ashton Thomas Private Wealth LLC purchased a new position in shares of Moderna in the second quarter valued at $26,000. Family Firm Inc. bought a new stake in shares of Moderna in the 2nd quarter valued at approximately $33,000. Hanseatic Management Services Inc. bought a new stake in shares of Moderna in the 2nd quarter valued at approximately $48,000. Plato Investment Management Ltd grew its stake in Moderna by 230.4% during the 2nd quarter. Plato Investment Management Ltd now owns 413 shares of the company's stock worth $49,000 after buying an additional 288 shares during the last quarter. Finally, Blue Trust Inc. boosted its position in Moderna by 365.6% during the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company's stock worth $49,000 after acquiring an additional 574 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Leerink Partners reduced their target price on Moderna from $60.00 to $48.00 and set an "underperform" rating for the company in a report on Tuesday, September 17th. Oppenheimer lowered Moderna from an "outperform" rating to a "market perform" rating in a research note on Friday, September 13th. UBS Group lowered their price target on shares of Moderna from $140.00 to $108.00 and set a "buy" rating for the company in a report on Thursday, October 24th. Wolfe Research assumed coverage on Moderna in a research note on Friday, November 15th. They issued an "underperform" rating and a $40.00 price target for the company. Finally, Royal Bank of Canada reiterated a "sector perform" rating and issued a $75.00 price target on shares of Moderna in a report on Thursday, September 19th. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $83.33.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 715 shares of the business's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares of the company's stock, valued at approximately $571,440.60. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Shannon Thyme Klinger sold 1,418 shares of the firm's stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,850 shares of company stock worth $134,560 over the last quarter. Company insiders own 15.70% of the company's stock.

Moderna Stock Performance

Shares of MRNA stock traded up $1.23 during trading on Thursday, reaching $42.86. 4,997,730 shares of the company's stock were exchanged, compared to its average volume of 4,910,244. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The firm's fifty day moving average price is $51.11 and its 200-day moving average price is $89.24. Moderna, Inc. has a twelve month low of $35.80 and a twelve month high of $170.47. The stock has a market capitalization of $16.49 billion, a PE ratio of -7.15 and a beta of 1.58.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company had revenue of $1.90 billion during the quarter, compared to analysts' expectations of $1.25 billion. During the same quarter last year, the company posted ($1.39) EPS. Moderna's quarterly revenue was up 3.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that Moderna, Inc. will post -9.32 EPS for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.